The Future Of Medicine: Cell And Gene Therapies Take The Lead
Risk-taking required, partnerships essential to advance the field
BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.
You may also be interested in...
Finance Watch: One Week Of IPOs Total $818.2m
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Quick Listen: Scrip's Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.
Dyno Therapeutics Emerges With Novartis, Sarepta Deals For Novel AAV Capsids
Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.